GSC
TCRT icon

G&S Capital’s Alaunos Therapeutics TCRT Stock Holding History

G&S Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30
Closed -$19K – 246
2019
Q3 		$19K Hold
30
– – 0.01% 146
2019
Q2 		$26K Sell
30
-7
-19% -$4.81K 0.02% 146
2019
Q1 		$21K Sell
37
-83
-69% -$34.7K 0.01% 150
2018
Q4 		$34K Sell
120
-82
-41% -$32.4K 0.03% 114
2018
Q3 		$97K Hold
202
– – 0.07% 97
2018
Q2 		$92K Hold
202
– – 0.07% 92
2018
Q1 		$119K Hold
202
– – 0.1% 77
2017
Q4 		$125K Buy
+202
New +$145K 0.09% 87

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

G&S Capital's TCRT Position: Q4 2019 in Review

G&S Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 30 shares — an estimated $19K sold.

G&S Capital first reported a position in TCRT in Q4 2017 and held it in 8 quarters. The position peaked at $125K in Q4 2017. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • G&S Capital reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • G&S Capital sold 30 Alaunos Therapeutics shares in Q4 2019, an estimated $19K.
  • G&S Capital first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 8 quarters.
  • G&S Capital's Alaunos Therapeutics position peaked at $125K in Q4 2017.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on G&S Capital's 13F filing for Q4 2019, filed 21 Jan 2020.